These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3484854)

  • 21. Seizures and action myoclonus after occupational exposure to methyl bromide.
    Prockop LD; Smith AO
    J Fla Med Assoc; 1986 Sep; 73(9):690-2. PubMed ID: 3772334
    [No Abstract]   [Full Text] [Related]  

  • 22. Parkinson's disease.
    Barboi AC; Goetz CG
    Clin Neuropharmacol; 1999; 22(4):184-91. PubMed ID: 10442246
    [No Abstract]   [Full Text] [Related]  

  • 23. Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
    Burkhard P; Dominici P; Borri-Voltattorni C; Jansonius JN; Malashkevich VN
    Nat Struct Biol; 2001 Nov; 8(11):963-7. PubMed ID: 11685243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serotonin models of myoclonus in the guinea pig and rat.
    Wolfson LI; Thal LJ; Brown LL
    Adv Neurol; 1986; 43():519-27. PubMed ID: 3484858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myoclonus and L-5-hydroxytryptophan (L-5HTP).
    Van Woert MH
    Prog Clin Biol Res; 1983; 127():43-52. PubMed ID: 6351100
    [No Abstract]   [Full Text] [Related]  

  • 26. Serotonergically active agents in levodopa-induced psychiatric toxicity reactions.
    Nausieda PA; Tanner CM; Klawans HL
    Adv Neurol; 1983; 37():23-32. PubMed ID: 6858774
    [No Abstract]   [Full Text] [Related]  

  • 27. Levodopa in pregnancy.
    von Graevenitz KS; Shulman LM; Revell SP
    Mov Disord; 1996 Jan; 11(1):115-6. PubMed ID: 8771087
    [No Abstract]   [Full Text] [Related]  

  • 28. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What to do when Sinemet fails: Part one.
    Klawans HL
    Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
    [No Abstract]   [Full Text] [Related]  

  • 30. Update on the treatment of Parkinson's disease.
    Wirz D
    Conn Med; 1985 Oct; 49(10):633-7. PubMed ID: 3933903
    [No Abstract]   [Full Text] [Related]  

  • 31. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
    García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
    Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
    Fermaglich J
    Med Ann Dist Columbia; 1974 Dec; 43(12):587-91. PubMed ID: 4532167
    [No Abstract]   [Full Text] [Related]  

  • 34. Ziprasidone for drug-induced psychotic symptoms in Parkinson's Disease.
    Duggal HS; Singh I
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):583-4. PubMed ID: 18022304
    [No Abstract]   [Full Text] [Related]  

  • 35. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathological findings in a case of hypoxic myoclonus treated with 5-hydroxytryptophan and a decarboxylase inhibitor.
    De Léan J; Richardson JC; Rewcastle NB
    Adv Neurol; 1986; 43():215-23. PubMed ID: 2418647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy: problems and practices.
    Muenter MD
    Clin Neuropharmacol; 1986; 9 Suppl 1():S23-36. PubMed ID: 3708606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Usefulness of increasing the proportion of carbidopa to levodopa in the long-term treatment of Parkinson's disease].
    Bermejo Pareja F; Martínez-Martín P
    Med Clin (Barc); 1984 Feb; 82(7):305-10. PubMed ID: 6717135
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
    Greene P; Cote L; Fahn S
    Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
    [No Abstract]   [Full Text] [Related]  

  • 40. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A; Sanchez-Ramos J
    Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.